Scarica l'app Stockscreener
32.14
0.50%
-0.16
Dopo l'orario di chiusura:
32.14
Precedente Chiudi:
$32.30
Aprire:
$31.77
Volume 24 ore:
874.49K
Relative Volume:
1.72
Capitalizzazione di mercato:
$1.25B
Reddito:
-
Utile/perdita netta:
$-74.31M
Rapporto P/E:
-12.95
EPS:
-2.4817
Flusso di cassa netto:
$-62.86M
1 W Prestazione:
+12.10%
1M Prestazione:
+15.61%
6M Prestazione:
+90.29%
1 anno Prestazione:
+930.13%
Intervallo 1D:
$29.88
$32.29
Intervallo di 1 settimana:
$27.40
$33.67
Portata 52W:
$3.046
$33.67
Alto Neuroscience Inc Stock (ANRO) Company Profile
Nome
Alto Neuroscience Inc
Settore
Industria
Telefono
773-255-5012
Indirizzo
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
32.14 | 1.13B | 0 | -74.31M | -62.86M | -2.4817 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Ripresa | Chardan Capital Markets | Buy |
| 2025-11-17 | Iniziato | BTIG Research | Buy |
| 2025-09-29 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-23 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-09-03 | Iniziato | Wedbush | Outperform |
| 2024-02-27 | Iniziato | Jefferies | Buy |
| 2024-02-27 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-27 | Iniziato | Stifel | Buy |
| 2024-02-27 | Iniziato | TD Cowen | Outperform |
| 2024-02-27 | Iniziato | William Blair | Outperform |
Mostra tutto
Alto Neuroscience Inc Borsa (ANRO) Ultime notizie
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued? - Yahoo Finance
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline? - Yahoo Finance
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans - Yahoo Finance
Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding - Sahm
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits
Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen - marketbeat.com
Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap - Stock Titan
Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A - Stock Titan
BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating - moomoo.com
Alto Neuroscience (NYSE:ANRO) Stock Price Down 4.7%Here's Why - marketbeat.com
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside - TradingView
Sirenia Capital (ANRO) discloses 2.22M Alto Neuroscience shares under beneficial ownership - Stock Titan
BofA Adjusts Price Target on Alto Neuroscience to $37 From $33 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT) - The Globe and Mail
Alto Neuroscience stock hits all-time high at 32.74 USD By Investing.com - Investing.com Australia
Alto Neuroscience stock hits all-time high at 32.74 USD - Investing.com
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat - marketbeat.com
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.11, Implies 27% Upside - TradingView
Wedbush Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock - marketbeat.com
Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, BTIG Research Analyst Says - marketbeat.com
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $36.89, Implies 26% Upside - TradingView
Alto Neuroscience Q2 EPS beats estimates; completes $100M financing - scanx.trade
Alto Neuroscience (NYSE:ANRO) Announces Quarterly Earnings Results - marketbeat.com
Alto Neuroscience (ANRO) boosts cash to $243.7M as R&D spend surges - Stock Titan
Alto Neuroscience Reports Q2 Loss As ALTO-207 Program Expands - Quiver Quantitative
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week HighShould You Buy? - marketbeat.com
Alto Neuroscience (ANRO) Earnings Date and Reports 2026 - marketbeat.com
Alto Neuroscience Escapes Investor Drug Trial Suit, For Now - Law360
Alto Neuroscience Inc (ANRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Shareholders SueWallSt in New Class Action Against Alto Neuroscience, Inc.Act Now - The National Law Review
Alto Neuroscience stock hits all-time high at 29.34 USD By Investing.com - Investing.com Australia
Alto Neuroscience (NYSE:ANRO) Sets New 12-Month HighShould You Buy? - MarketBeat
Alto Neuroscience stock hits all-time high at 29.34 USD - Investing.com
Alto Neuroscience (ANRO) Projected to Announce Earnings on Wednesday - marketbeat.com
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Alto Neuroscience, Inc. (ANRO) - The National Law Review
Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications (ANRO) - Seeking Alpha
Perceptive Advisors LLC Buys 225,500 Shares of Alto Neuroscience, Inc. $ANRO - MarketBeat
BlackRock, Inc. Expands Stake in Alto Neuroscience Inc (ANRO) wi - GuruFocus
Alto Neuroscience Inc (ANRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ANRO|Alto Neuroscience Inc|Price:27.910|Chg%:+1.130 - TradingKey
BlackRock (ANRO) discloses 6.0% beneficial ownership in Alto Neuroscience common stock - Stock Titan
ANRO|Alto Neuroscience Inc|Price:27.350|Chg%:+0.570 - TradingKey
Alto Neuroscience Inc (ANRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alto Neuroscience Inc (ANRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alto Neuroscience Inc (ANRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alto Neuroscience Inc. (ANRO) Gains Momentum: Approaching Key ResistanceSmall Cap Breakouts - dars.gov.et
Alto Neuroscience Inc (ANRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alto Neuroscience Inc Azioni (ANRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):